Sarcopenia and early-stage bladder cancer prognosis
Part of Bones, joints & muscles, Cancer clinical trials.
This study looks at whether loss of muscle mass (sarcopenia) affects outcomes for people with early-stage bladder cancer. It may help doctors predict how the disease will progress and plan better care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with early-stage bladder cancer that has not invaded the muscle layer.
- You are scheduled for a procedure to remove the tumor from your bladder (TURBT).
- You are able to have a CT scan to measure your muscle mass.
- You have completed routine pre-surgery tests, including blood work and measurements like weight and waist size.
- You are willing and able to provide written consent and follow up with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how muscle loss (sarcopenia) affects people diagnosed with colorectal cancer before age 50. It uses CT or MRI scans taken at diagnosis to measure muscle mass and see how it relates to treatment and outcomes.
This study looks at how muscle loss (sarcopenia) might affect side effects from cancer treatments. If you are starting a new cancer treatment, a CT scan before treatment can help doctors predict your risk of side effects.
This trial looks at whether low muscle mass (sarcopenia) before surgery affects recovery for older adults with gastrointestinal cancer. It may help doctors personalize care and improve outcomes.
This study looks at tumor and blood samples from people with muscle-invasive bladder cancer to find markers that help predict how the disease will progress. It aims to improve personalized treatment for those with this specific stage of bladder cancer.
This study looks at how well a standard chemotherapy given before surgery works for muscle-invasive bladder cancer. It aims to see if higher responses lead to better outcomes.
This study watches people with muscle-invasive bladder cancer who choose to keep their bladder after receiving neoadjuvant therapy (treatment before the main treatment). It aims to see how well bladder-preserving treatments like chemoradiation work over time.
Hear when a new Bladder Cancer Cell Transitional trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.